PT
PTC Therapeutics
PTCT · NASDAQ
$69.30 -1.87% (-$1.32)
1M -5.47%
Market Cap $5.96B
P/E Ratio -
Div. Yield -
ROE -
Bulios Fair Price
$80.56
16.2% upside
Current Price
$69.3
Undervalued Fair Value Overvalued
According to Bulios Fair Price, PTCT is currently undervalued relative to its market price. How does it work?
Bulios Fair Price is an estimate of a stock's fair value from the Bulios valuation model. It is an input for your own analysis, not investment advice. How does it work?
Piotroski F-Score Weak
2/9Valuation
7 /100
Expensive EV/EBITDA 32.31x
P/S 5.91x
P/E N/A
Growth
100 /100
Growing Rev. growth 35.30%
EPS growth N/A
FCF growth N/A
Profitability
34 /100
Moderate Gross margin 82.14%
Net margin 3.80%
Op. margin 11.52%
Quality
11 /100
Poor ROIC 2.61%
ROA 1.18%
Asset turnover 0.31x
Debt
74 /100
Low Current ratio 3.39x
Int. coverage 0.64x
Net debt/EBITDA -2.04x
Stability
25 /100
Unstable Beta 0.55x
Rev. volatility 64.91%
EPS volatility 144.56%
Bulios Scoring describes a company's quality and track record, not its future return. A high score is not a buy signal. Learn more
Ask StockBot about PTCT
Online
Sector
Healthcare
Industry
Biotechnology
CEO
Matthew Klein
Employees
991
Headquarters
Warren
Upcoming events
03 NOV
Earnings
Upcoming earnings report